Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ambrosia confertiflora pollen extract, derived from slimleaf ragweed, is a biological allergen extract used for both the diagnosis and treatment of ragweed-induced allergic conditions. As a diagnostic tool, it is utilized in skin prick or intradermal testing to identify IgE-mediated hypersensitivity. Therapeutically, it is administered via subcutaneous immunotherapy (SCIT), where gradual exposure to increasing doses of the allergen induces immunological tolerance. This process involves shifting the immune response from a Th2-mediated allergic profile to a Th1 and regulatory T-cell (Treg) response, leading to the production of IL-10 and IgG4 blocking antibodies, which compete with IgE for allergen binding, and a subsequent reduction in mast cell and basophil activation and mediator release.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ambrosia confertiflora pollen extract.